8253 results for "canc*"

in 14.20 milliseconds.

• Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma - WGS validation cohort

  This reposiroty contains bulk WGS data generated by Blood Cancer Research Group (Ostrava, Czech Republic) as a part of publication named "Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma" published in Hemapshere.

  Study EGAS50000001211

• Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma - RNA validation cohort

  This reposiroty contains bulk RNA data generated by Blood Cancer Research Group (Ostrava, Czech Republic) as a part of publication named "Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma" published in Hemapshere.

  Study EGAS50000001212

• Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma - WGS

  This reposiroty contains bulk WGS data generated by Blood Cancer Research Group (Ostrava, Czech Republic) as a part of publication named "Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma" published in Hemapshere. The dataset contains 11 tumor-normal sample pairs.

  Dataset EGAD50000001724

• Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma - RNA

  This reposiroty contains bulk RNA data generated by Blood Cancer Research Group (Ostrava, Czech Republic) as a part of publication named "Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma" published in Hemapshere. The dataset contains RNAseq samples from bone marrows.

  Dataset EGAD50000001725

• Cancer Genomics Lab at Johns Hopkins

  Dac EGAC00001003656

• Pan Prostate Cancer Group Germany BAM files

  German early-onset prostate cancer whole-genome sequencing samples of the Pan-Prostate Cancer Genome (PPCG) project. Whole Genome Sequencing Illumina data from men with prostate cancer. Samples were taken from primary tissue obtained at prostatectomy with matched blood control.

  Dataset EGAD00001005997

• DAC for Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers

  Ovarian cancer is a leading cause of death from gynecological malignancies worldwide. No effective screening methods exist resulting in tumor detection at advanced stages where treatment is less effective. In this study, we used whole-genome cell-free DNA (cfDNA) fragmentome and protein biomarker (CA-125 and HE4) analyses to evaluate 591 women, mostly post-menopausal, from the European Union or the United States with ovarian cancer, benign adnexal masses, or without ovarian lesions. Using a machine learning model that incorporated multi-analyte fragmentome data and protein measurements, we evaluated the detection of ovarian cancer in two clinical settings, detection of ovarian cancers among a healthy population, and classification of adnexal masses as benign or malignant. The combined approach detected ovarian cancer with specificity >99% and sensitivity of 72%, 69%, 87%, and 100% for stages I–IV, respectively (AUC=0.96, 95% CI: 0.94-0.99), including 90% of high grade serous ovarian cancers. At the same specificity, CA-125 alone detected 34%, 62%, 63%, and 100% of ovarian cancers for stages I–IV (p=0.001, two-sided test of equal proportions). Additionally, our approach differentiated benign masses from ovarian cancers with high accuracy (AUC of 0.88, 95% CI=0.83-0.92). These results were validated in an independent population. These findings show that integrated cfDNA fragmentome and protein analyses detect ovarian cancers with high performance, enabling a new accessible approach for noninvasive ovarian cancer screening and diagnostic evaluation.

  Dac EGAC50000000332

• Prefibrotic Bone Marrow Microenvironment is a Hallmark of Clonal Hematopoiesis

  Clonal hematopoiesis of indeterminate potential (CHIP) is linked to systemic inflammation and increased malignant risk, yet its impact on the bone marrow (BM) niche remains poorly understood. Through single-cell transcriptomic profiling of freshly isolated BM, we identify fibro-inflammatory rewiring as an early hallmark of CHIP. Beyond a myeloid-biased inflammatory state, CHIP BM exhibited coordinated TNFα activation across hematopoietic progenitor, monocyte, and stromal compartments. Stromal populations displayed early fibrotic remodeling, with mesenchymal and vascular cells upregulating collagen and extracellular matrix programs. Fibroblasts were markedly expanded independent of mutational subtype and acquired cancer-associated fibroblast (CAF)-like programs, rewiring niche interactions through IL-6, TGFβ, and collagen-integrin signaling. Together, these findings establish fibro-inflammatory BM remodeling as an early hallmark of clonal expansion, linking CHIP to prefibrotic stromal remodeling, immune dysregulation, and a niche architecture consistent with increased malignant risk.

  Study EGAS50000001774

• NICHE - Pre-treatment single cell RNA-seq of MMR proficient early stage colon cancers

  This dataset includes raw single cell RNA sequencing data from 13 pMMR colon cancer patients treated with neoadjuvant immune checkpoint blockade in the NICHE trial. This dataset comprises pre-treatment colon cancer biopsy samples, which digested to obtain single cell suspensions, sorted for CD45+, labelled with hashtag antibodies, split in 3 cell pools, and distributed in 5 sequencing samples (7654_1-5). 30 FASTQ files were generated, 10 files for scRNAseq gene expression (10X Genomics Chromium Next GEM Single Cell 5' v2), 10 files for single cell TCRseq (10X Genomics Chromium Next GEM Single Cell V(D)J Reagent Kits 5' v2) and 10 files for feature barcodes and hashtag antibodies, with feature reference barcodes provided. Samples were sequenced on Illumina Novaseq 6000 and raw FASTQ files were later processed with Cellranger workflows from 10X Genomics, investigating features of pre-treatment immune tumour cells and associations with neoadjuvant response.

  Dataset EGAD50000002853

• Pre-existing immunity and hrHPV status as determinants of immunotherapy response in advanced penile cancer: biomarkers and overall survival in the PERICLES trial

  The phase II PERICLES trial (NCT03686332) investigated atezolizumab with or without radiotherapy in advanced penile cancer. Here, we report mature overall survival (OS) and updated progression-free survival (PFS) outcomes and an in-depth biomarker analysis. The goal was to perform an in-depth assessment of the tumor microenvironment to identify potential predictive biomarkers and cellular mechanisms underlying successful PD-L1 blockade response.

  Study EGAS50000001571

• DAC Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive, HER2-negative breast cancer patients.

  DAC for Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive, HER2-negative breast cancer patients.

  Dac EGAC50000000694

• NeoLetExe clinical trial single-cell RNA-seq, scTCR-seq, scBCR-seq and cis-regulatory elements mapping

  We performed single cell RNA sequencing, single cell T cell receptor and B cell receptor sequencing on breast tumor biopsies collected from patient of the NeoLetExe clinical trial at 3 time points of neoadjuvant therapy with aromatase inhibitors. The NeoLetExe study is a randomized open-label clinical trial aimed at evaluating the effects of sequential aromatase inhibition in postmenopausal women with ER-positive, HER-2 negative locally advanced breast cancer (stages T3-T4 and/or N2-3, including larger T2 tumors). Fresh tumor biopsies were dissociated at the single cell level which when then processed using the 10x Genomics Chromium platform, using the Single-Cell 5′ RNA-seq method along with single cell BCR and TCR-seq. The target was 7,500 to 10,000 cells per well, with libraries prepared using Gel Bead, Multiplex, and Chip Kits, following the manufacturer’s guidelines. Sequencing was performed on NovaSeq6000. We used SCAFE v1.0.065 to identify TSSs and map transcriptionally active regulatory elements.

  Study EGAS50000001362

• Cell-Free DNA Fragmentation Distinguish Immunotherapy Responders from Non- Responders in Head and Neck Cancer: A Multi-Institute Prospective Study

  We performed whole-genome sequencing of 185 plasma cfDNA samples from 68 patients with head and neck squamous cell carcinoma (HNSCC) enrolled in a phase II clinical trial of neoadjuvant and adjuvant pembrolizumab. Using these data, we developed the regional motif diversity score (rMDS), a novel fragmentomic biomarker that predicts immunotherapy response and outperforms established cfDNA metrics.

  Study EGAS50000001286

• IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Italian Cancer Center Data Access Committee

  Dac EGAC00001003631

• Genetic, epigenetic and fragmentomic profiling of plasma cell-free DNA in cancer patients

  The primary goal of the study is to explore the temporal changes in cfDNA profiles in liver cancer patients undergoing therapeutic treatment. Serial blood collection and plasma cfDNA analysis were performed in patients with liver cancer, including patients with primary hepatocellular carcinoma, or those with secondary liver metastasis. Various molecular features of cfDNA were studied, including tumor fraction, epigenetic and fragmentomic analysis.

  Study EGAS50000002022

• Ex vivo therapy-driven selection of glioblastoma stem-like cells models resistance evolution

  Glioblastoma (GBM) remains lethal, creating an urgent need for experimental models of therapy- specific resistance evolution. Within-patient GSC models were developed by parallel ex-vivo selection under temozolomide (TMZ-GSC) or ionizing radiation (IR-GSC), alongside untreated controls (CTRL- GSC). • O6-methylguanine-DNA methyltransferase (MGMT) expression was confirmed as a determinant of primary TMZ resistance and was maintained during GSC evolution. • In MGMT-negative GSCs, primary TMZ sensitivity evolved into stable secondary resistance through mismatch-repair gene inactivation, recapitulating patient findings, or was retained along with a newly identified drug-tolerant phenotype. • Primary radioresistance was commonly observed, while its further evolution was associated with more efficient DNA double-strand-break repair and enrichment of homologous- recombination and checkpoint-control transcriptional programs. • In GSCs emerging after either TMZ or IR, broad transcriptional patient-specific programs and classification-relevant subtypes were largely preserved. • Across treatments, GSC evolution was accompanied by shared genome-maintenance and mitotic chromosome-segregation transcriptional programs and increased RTK expression and activity, collectively promoting recovery after genotoxic stress.

  Study EGAS50000002011

• Genetic, epigenetic and fragmentomic profiling of plasma cell-free DNA in cancer patients

  The uploaded data includes sequencing of plasma cfDNA from a total of 33 cancer patients. Plasma cfDNA samples were sequenced for whole-genome sequencing analysis using double-stranded DNA libraries, and paired bisulfite sequencing using single-stranded DNA libraries. All sequencing data are of extracted plasma cfDNA from human patients, and sequenced using the Illumina NovaSeq6000 platform. Alignment was performed to the human genome (hg19). Lambda DNA was added to samples subjected to bisulfite sequencing for quality control.

  Dataset EGAD50000002912

• Nicotinamide phosphoribosyltransferase is an integrator of circadian clock regulation and NAD+ metabolism in liver cancer

  NAMPT is a liver-specific integrator of circadian and metabolic regulation, and its dysregulation creates a therapeutic window for a more precise treatment of liver cancer.

  Study EGAS50000000868

• The Precision Medicine in Liver Cancer across an Asia-pacific NETwork (PLANET) – HCC recurrence cohort

  Hepatocellular carcinoma (HCC) is a highly fatal cancer marked by significant intra-tumor heterogeneity (ITH). Given 50% to 70% of HCC patients experience recurrence, understanding the origins and progression of recurrence is crucial. To address this, we assembled a multi-sector, paired HCC recurrence cohort of 24 patients, including comprehensive whole genome sequencing and transcriptome samples. Through this longitudinal cohort, we aimed to trace the origins of recurrence and identify molecular features associated with early recurrence. These insights may improve predictions of early HCC recurrence and inform potential therapeutic strategies.

  Study EGAS50000000869

• The dataset for Genomic landscapes of endometrioid and mucinous ovarian cancers and morphologically similar tumor types

  The dataset for “Genomic landscapes of endometrioid and mucinous ovarian cancers and morphologically similar tumor types” includes 288 bam files from whole genome, whole exome and targeted next-generation sequencing on the Illumina HiSeq2500 and MiSeq. The samples analyzed include tumor and normal tissue samples from patients with cancer.

  Dataset EGAD50000000744

• The dataset of Detection and characterization of lung cancer using cell-free DNA fragmentomes on NovaSeq 6000 at 1-2x coverage

  The dataset contains 364 CRAM files from whole-genome next-generation sequencing on the Illumina NovaSeq 6000 at 1- 2x coverage. These are plasma samples from healthy individuals and patients with cancer.

  Dataset EGAD50000001961

• Analysis of Somatic Mutations from Liquid Biopsy-Derived cfDNA in Advanced Cancers

  This study aims to identify somatic mutations and characterize potential neoantigens for immunotherapeutic targeting using paired whole-exome sequencing (WES) of germline DNA and plasma-derived circulating cell-free DNA (cfDNA) from patients with advanced-stage cancers.

  Study EGAS50000001169

• Analysis of Somatic Mutations and Neoantigen Landscape from Liquid Biopsy-Derived cfDNA in Advanced Cancers

  This study involves paired whole-exome sequencing (WES) of germline DNA and plasma-derived circulating cell-free DNA (cfDNA) from patients with advanced-stage cancers, aiming to identify somatic mutations and characterize potential neoantigens for immunotherapeutic targeting.

  Dac EGAC50000000717

• Validation of cfDNA fragmentome analyses for early detection of liver cancer

  Study EGAS00001008111

• Methylation data for Genomic landscapes of endometrioid and mucinous ovarian cancers and morphologically similar tumor types

  Study EGAS00001008175